Logotype for Syngene International Limited

Syngene International (SYNGENE) Q4 25/26 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Syngene International Limited

Q4 25/26 earnings summary

4 May, 2026

Executive summary

  • FY 2026 saw muted top-line growth of 3% year-on-year, with Q4 delivering a strong 13% sequential rebound despite Librela headwinds; Q4 revenue from operations grew 2% year-on-year to Rs 1,037 Cr.

  • FY 2027 is expected to be a transition year with leadership changes, a strategic reset focusing on CDMO, biologics, and AI-enabled service lines, and new executive appointments.

  • Investments in AI, digital technologies, and infrastructure are aimed at improving operational efficiency and creating differentiated offerings.

  • Recognized for sustainability, ranking among the world's most sustainable companies by TIME, S&P Global, and Statista.

  • Audited financials for FY 2026 were approved, with a final dividend of ₹1.25 per share recommended and new statutory auditors appointed.

Financial highlights

  • Q4 FY26 revenue from operations was INR 1,037 crore (Rs 10,365 Mn), up 2% year-on-year and 13% sequentially; full-year revenue grew 3% to Rs 37,387 Mn.

  • Q4 operating EBITDA was INR 303 crore with a margin of 29%; FY26 EBITDA margin was 25–26%, down from 29–30% last year.

  • Profit after tax before exceptional items for FY 2026 was INR 380 crore (Rs 3,799 Mn), down 20% year-on-year; consolidated net profit was Rs 3,167 Mn.

  • Free cash generated during the year was INR 521 crore; net cash balance at year-end was INR 1,800 crore (Rs 18,003 Mn).

  • Basic EPS (consolidated) for FY 2025-26 was ₹7.87, compared to ₹12.35 in FY 2024-25.

Outlook and guidance

  • FY 2027 is expected to have broadly flat performance due to continued impact from Librela, with EBITDA margins guided in the mid-20s.

  • Q1 and Q2 FY 2027 will see almost no Librela revenue, with minor volumes in the last quarter; growth is expected to resume from FY 2028 as new capabilities and contracts mature.

  • Continued focus on expanding integrated drug discovery and manufacturing capabilities, especially in ADCs and biologics.

  • Ongoing investments in infrastructure and technology are expected to support future growth.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more